ICER plans cloud-based tools to accelerate the use of value assessments in the US health care system

20 May 2019 - With a late 2019 launch target, ICER’s Evidence Compendium and Interactive Modeler will enable decision-makers within payers, ...

Read more →

Congress should revive the Office of Technology Assessment

13 May 2019 - In recent decades, the U.S. economy and society have been propelled forward by a boom in science ...

Read more →

Institute for Clinical and Economic Review's evidence report finds esketamine may benefit patients with treatment-resistant depression but exceeds cost-effectiveness thresholds

9 May 2019 - Midwest CEPAC to vote on overall value of esketamine during 23 May public meeting. ...

Read more →

ICER publishes evidence report on the use of siponimod to treat secondary progressive multiple sclerosis

2 May 2019 - Midwest CEPAC to deliberate on the treatment’s clinical effectiveness and other potential benefits during its May ...

Read more →

ICER seeks public input for 2020 value assessment framework

2 May 2019 - Accepting Open Input Through 10 June 2019. ...

Read more →

ICER posts draft scoping document for the assessment of treatments for type 2 diabetes mellitus

2 May 2019 - Document open to public comment until 22 May 2019. ...

Read more →

ICER's growing impact on drug pricing and reimbursement

17 April 2019 - The Institute for Clinical and Economic Review is sometimes called America's `NICE,’ referring to the National ...

Read more →

The perils of value based pricing for prescription drugs

11 April 2019 - How do you determine the value, and the price, of life-saving medication? ...

Read more →

Institute for Clinical and Economic Review posts draft scoping document for the assessment of treatments for rheumatoid arthritis

11 April 2019 - Document open to public comment until 1 May 2019. ...

Read more →

Institute for Clinical and Economic Review to assess treatments for type 2 diabetes mellitus

11 April 2019 - Report will be subject of New England CEPAC meeting in November 2019; open Input now being ...

Read more →

Institute for Clinical and Economic Review releases draft evidence report on treatments for peanut allergy

9 April 2019 - Public comment period now open until 8 May 2019; requests to make oral comment during public ...

Read more →

Gene therapy was hailed as a revolution. Then came the bill.

7 April 2019 - Cost of new treatments may run into the millions of dollars. ...

Read more →

ICER issues final report on Spinraza and Zolgensma, provides policy recommendations related to pricing and coverage of treatments for spinal muscular atrophy

3 April 2019 - Independent appraisal committee notes family testimony in votes confirming broad benefits of both treatments; however, committee votes ...

Read more →

Institute for Clinical and Economic Review Appoints Dr. Pamela Bradt as Chief Scientific Officer

2 April 2019 - The Institute for Clinical and Economic Review has announced the appointment of Pamela Bradt as the organization's ...

Read more →

When is the price of a drug unjust? The average lifetime earnings standard

1 April 2019 - The majority of Americans believe that lowering drug prices should be the top health care priority for ...

Read more →